STOCKS TELEGRAPH

Author: Mahrukh Rehan

  • Just Eat Takeaway.com N.V. (GRUB) stock has experienced a downfall – What’s happening?

    Just Eat Takeaway.com N.V. (GRUB) stock has experienced a downfall – What’s happening?

    Just Eat Takeaway.com N.V. (GRUB) saw a decrease of 5.36% in premarket following the update in SEC filing. However, the last trading session closed at $9.89 with a decrease of 0.60%.

    Launch of $2 Million Grant Program by GRUB – More About it

    It was announced on 12th January 2022 that the United States Hispanic Chamber of Commerce Educational Fund has partnered with GRUB. Small companies have had an especially difficult 18 months. And the company thinks that it must help them to stay a part of the communities’ fabric. Moreover, the company is happy to partner with the USHCC and provide this critical assistance to Hispanic-owned restaurants as they struggle to recover.

    GRUB: What’s Next?

    Now, more than ever, the restaurant businesses will require access to the services and tools provided by the USHCC national network as they fight to reopen their doors and recover. Moreover, as the company seeks to revive the economy and bring people back to work, many of the Hispanic-owned restaurants that have managed to stay open and not entirely shut down are searching for advice and help. GRUB happily partners on this critical endeavor, and the team admires all the efforts to help minority-owned eateries.

    Greg Hill Foundation’s Restaurant Strong Fund – What is it?

    On 21st December 2021, GRUB announced that the recipients of grants are awarded through the All Day Campaign. The firm granted over $4 million to 379 eateries across the country that have worked tirelessly to combat the epidemic. The grants, which range from $5,000 to $50,000, will assist restaurant owners in funding advancements to indoor and outdoor dining, equipment and technology maintenance and repairs, advertising and sales efforts, staff hiring and training, Covid-19 compliance, and infrastructural developments. In the past year, Grubhub and The Greg Hill Foundation have collaborated on three restaurant support programs.

    Now what?

    The company is happy to help these nearly 400 restaurants around the country as they recover from the pandemic and continue to serve their communities. Moreover, restaurant owners are tremendously resilient, and the company is happy that this money will benefit their businesses while speaking with recipients. Lastly, GRUB is excited about the restaurant industry’s future, and they will keep doing everything to help the businesses

  • Infobird Co., Ltd (IFBD) stock is decreasing to 7.44% – What’s going on?

    Infobird Co., Ltd (IFBD) stock is decreasing to 7.44% – What’s going on?

    Infobird Co., Ltd (IFBD) experienced a decrease of 7.44% in premarket. However, the last trading session closed at $1.21 with an increase of 29.41%.

    Contract with Subsidiary of Nippi Japan – Worth it?

    On 2nd February 2022, IFBD announced that it had signed an agreement with Contract with Nippi (Shanghai) Trading Co., Ltd. Nippi Shanghai will benefit from Infobird’s comprehensive digital marketing solutions, which will provide them with a multi-channel, intelligent marketing system that will improve their advertising efficiency and performance. Moreover, Infobird has a lot of experience with digital marketing and has worked with a lot of companies in different areas like banking, automotive, and retail.

    Moreover, marketing, customer reach, customer contact center, and customer lifecycle engagement are all addressed by the company’s cloud call center. Furthermore, IFBD can help Nippi Shanghai achieve its goal of improving customer operations and services from a variety of angles, in addition to digital marketing. Last but not the least, Infobird plans to expand its partnership with Nippi Shanghai in the future, as well as the use of its digital solutions in the big and rapidly growing health and wellness market.

    Acceleration of Marketing Solution by IFBD– More About it

    IFBD reported on 27th January 2022 that the Company has expanded its marketing and sales operations to seek further prospects in the fast-increasing EV carmaker industry. This is done as a consequence of the deployment of its digital marketing solution with HYCAN, a rising New Energy Vehicle manufacturer in China. Furthermore, the company recently introduced Infobird technology is intended to assist new energy vehicle manufacturers with marketing and customer interaction.

    Infobird’s entry into the sphere of new energy vehicles is a significant expansion initiative aimed at promoting the company’s standard SaaS strategy more broadly. Lastly, Infobird intends to improve cross-industry service capabilities, contribute to the company’s new energy vehicle business development, and give new growth potential.

    Contract for Digital Banking Solution by IFBD – What’s Next?

    On 11th January 2022, IFBD reported that it has agreed to a deal with Changchun Rural Commercial Bank for the deployment of the Company’s digital banking service. It is designed to be a user-friendly solution for banks looking to modernize their business and operations. Moreover, Changchun Rural Commercial Bank will boost omnichannel integration and intelligent customer interaction model by implementing Infobird’s online and intelligent banking solutions. In addition, through standardization and customization services, Infobird will assist Changchun Rural Commercial Bank in the development of contemporary digital and intelligent customer care center.

  • Quantum Corporation (QMCO) stock is moving down in aftermarket – Here’s what you should know

    Quantum Corporation (QMCO) saw a decrease of 29.90% in aftermarket following the announcement of Third Quarter Fiscal 2022 Results. However, the last trading session concluded at $4.95 with an increase of 5.10%.

    Third Quarter Fiscal 2022 Results – More About it

    QMCO announced Third Quarter Fiscal 2022 Results on 9th February 2022. The company recorded revenue of about $95.3 million with an incline of 2%. Moreover, the total operating expenses came out to be $42.4 million with selling and administrative expenses around $27.3 million. Furthermore, GAAP net loss recorded was $11.1 million. Last but not the least, the cash and cash equivalents are $4.3 million.

    Data-Intensive Autonomous Vehicle Research by QMCO – What’s up?

    On 5th January 2022, QMCO announced its contribution to the Center for Advanced Vehicular Systems (CAVS) at Mississippi State University (MSU) in boosting all-terrain autonomous vehicle research. Quantum R-Series Edge Storage, a high-performance is a ruggedized system designed for capturing enormous data volumes in edge locations. It will be used by CAVS to capture massive quantities of information. Moreover, vehicles that gather data are then analyzed and used in the CAVS data center to construct machine learning (ML) models.

    Furthermore, CAVS engineers can make data easily accessible to numerous development groups by combining the Quantum R-Series Edge Storage into a single storage platform. Technicians can help eliminate the memory magazine from the in-car backup system and slide it into a data center chassis, or they can use the 10-GbE network interface to offload the acquired vehicle data.

    Now what?

    Data is a critical component in enabling the automated car market’s continuous survival and prosperity. In addition, partnering with the CAVS team is a fantastic chance and would provide a data analysis solution that simplifies and streamlines the storage, movement, and analysis of crucial field data for the CAVS engineering team.

    About QMCO

    Quantum’s end-to-end platform is built on more than 40 years of the invention. Not only this but it is ideally positioned to organize, safeguard, and enrich data throughout its lifecycle. This further results in enhanced intelligence and actionable insights. Because data makes life better, safer, and smarter, leading companies in cloud services, entertainment, government, research, education, transportation, and business IT entrust Quantum with bringing their data to life.

  • Seagen Inc. (SGEN) stock is down in aftermarket – Let’s see why?

    Seagen Inc. (SGEN) experienced a decrease of 16.20% in the aftermarket because the company announced the fourth quarter and full-year 2021 results. However, the last trading session closed at $141.41 with an increase of 1.01%.

    Fourth Quarter and Full Year 2021 Results by SGEN

    SGEN announced fourth-quarter and full-year 2021 results on 9th February 2022. The company experienced revenue of about $429.9 million and $1.574 billion in the fourth quarter and full-year respectively. Moreover, TUKYSA and PADCEV were the primary contributors to the rise in net product sales in 2021 compared to the comparable periods in 2020. Moreover, TUKYSA’s growth was fueled by the company’s existing indication’s continuous penetration in the United States, as well as its global expansion following approval in the European Union in February 2021.

    Continued penetration in the initial indication, as well as FDA approval for PADCEV’s usage in another indication in July 2021, fueled PADCEV’s growth. ADCETRIS saw a modest rise as well, which was attributed in part to increased use in frontline advanced Hodgkin lymphoma. In September 2021, the FDA finally gave TIVDAK its approval. Lastly, the net loss came out to be $174.6 million and $674.5 million in the fourth quarter and full-year respectively.

    Now what?

    Strong net product sales, as well as worldwide releases of TUKYSA and the approval and launch of TIVDAK, the fourth commercial product, drove total revenues of $1.6 billion in 2021. Moreover, through comprehensive clinical development projects aimed at supporting label expansions, the company is trying to maximize the potential of the commercial portfolio.

    In addition, the company is developing a pipeline of over thirteen clinical-stage initiatives for solid tumors and hematological malignancies. In 2022, SGEN plans to hit a number of significant milestones, including significant clinical data readouts, worldwide regulatory and commercial developments, and pipeline advancements. Last but not the least, SGEN is well-positioned to continue executing the vision, with tremendous financial strength and a larger regional reach.

  • 2U, Inc. (TWOU) stock is experiencing a downfall – Here’s what is happening?

    2U, Inc. (TWOU) stock is experiencing a downfall – Here’s what is happening?

    2U, Inc. (TWOU) experienced a decrease of 22.97% in aftermarket following the announcement of full year and fourth quarter 2021 results. However, the last trading session closed at $17.98 with an increase of 3.69.

    Full Year and Fourth Quarter 2021 Results – More About it

    TWOU announced full year and fourth quarter 2021 results. The company experienced $945.7 million in revenue in full-year and $243.6 million in the fourth quarter of 2021. Moreover, the degree program segment revenue inclined by 22% and 17% in full-year and fourth quarter respectively. Not only this but Adjusted EBITDA came out to be $66.6 million in full-year whereas $21.0 million in the fourth quarter. Last but not the least, the company had a great year in 2021, and they finished strong.

    TWOU ended the year on a high note, with double-digit sales growth and improving margins. In addition, in the fourth quarter, the company completed the transformational acquisition of edX, and the effective integration of that transaction is a top priority for them. Given the digital marketing environment, the team believes that the forecast for 2022 reflects a disciplined growth plan and ongoing progress toward profitability. They have created a strategy and financial framework for accomplishing the mid-term goals and producing shareholder value with the inclusion of edX and the shift to a platform company.

    Partnership of TWOU with The University of Sydney

    On 9th February 2022, TWOU announced that it had partnered with The University of Sydney in order to offer post-graduate degrees online. The collaboration will provide four postgraduate degrees online, starting with a Master of Data Science and a Master of Project and Program Management, with applications opening in August 2022 and classes starting in February 2023. Most postgraduate students, who are typically working full-time, can choose to attend classes online.

    What’s Next?

    TWOU must participate in numerous ways, for the needs of all the students, and to a world-class standard, if the University is to be partners in lifelong learning with the community. Moreover, the collaboration with 2U allows for that flexibility, and it will give the company a new way to meet the students’ needs.

    Because of COVID, the team was able to achieve an outstanding outcome in swiftly transitioning online. This agreement allows the team to gain additional capacity and upskilling in this area much more quickly than would be possible through exclusively in-house development, thanks to the highly experienced and well-regarded 2U.

  • Sonos, Inc. (SONO) stock is moving up in the aftermarket – What’s driving it high?

    Sonos, Inc. (SONO) stock is moving up in the aftermarket – What’s driving it high?

    Sonos, Inc. (SONO) has seen an increase of 6.42% in the aftermarket because the company announced its first-quarter fiscal year 2022 results. However, the last trading session concluded at $26.65 with an increase of 0.23%.

    First Quarter Fiscal Year 2022 Results by SONO – What’s up?

    SONO announced the first-quarter fiscal year 2022 results on 9th February 2022. The company announced a revenue of $664.5 million with a 3% increase year over year. Moreover, the gross margin came out to be 47.8% with an incline of 47.8%. Not only this but GAAP net income totaled $123.5 million with adjusted EBITDA of $163.1 million. Furthermore, cash flow from operating activities was $179.9 million. Last but not the least, free cash flow reported was around $173.6 million.

    Now what?

    The company is thrilled to report that Sonos had another good quarter, with record revenue of $664.5 million and a strong adjusted EBITDA margin of 24.6 percent despite continuing to invest in the company. Importantly, SONO believes that they would have sold a lot more if it hadn’t been for chip shortages that limited the supply, as demand was high. The company has increased the midpoint of the projection to reflect the fact that the operations team has established tremendous resiliency and that they are well-positioned to deliver on the fiscal 2022 outlook.

    In the long run, Sonos has a huge chance. The combination of modern household generation and existing client repurchases continues to be a strong growth engine. Furthermore, to satisfy existing customers and attract new ones, the company has a fantastic product plan. Lastly, SONO thinks that it will grasp the future and produce significant shareholder value in the long run, with a 2% sales volume of the $89 billion worldwide audio markets.

    Long-term Sustainability Commitment by SONO – What’s New?

    On 8th December 2021, SONO reported that as part of its commitment to a more sustainable future, the company unveiled its first Climate Action Plan. By following the plan, Sonos’ value chain will be carbon neutral by 2030 and net-zero by 2040. The company detailed the idea in Sonos’ 2021 Listen to Better Report, which provides an annual assessment of the company’s ESG activities.

    The company is entering into a new era where it will focus on environmental responsibility with the Climate Action Plan, scaling up the efforts to decrease the effect across the board. Lastly, SONO is an innovative firm that thrives on the challenge of developing better products for the consumers and the environment.

  • Twilio Inc. (TWLO) is skyrocketing in the aftermarket – Latest News

    Twilio Inc. (TWLO) is skyrocketing in the aftermarket – Latest News

    Twilio Inc. (TWLO) experienced an increase of 18.21% in aftermarket following the announcement of the fourth quarter and full-year 2021 results. However, the last trading session closed at $202.01 with an increase of 1.76%.

    Fourth Quarter Results in 2021 – What’s up?

    TWLO announced fourth-quarter results on 9th February 2022. The company experienced revenue of $842.7 million. Not only this but the GAAP loss from operations came out to be $283.6 million whereas non-GAAP loss from operations totaled $27.2 million. Last but not the least, organic revenue increased by 34% year over year, and by 39% when political traffic revenue was excluded.

    The full Year 2021 Financial Results – More About it

    TWLO reported full-year 2021 financial results on 9th February 2022. According to the report, the revenue for the entire year reported was $2.84 billion. Not only this but organic revenue increased by 42% year over year for the whole year. Moreover, GAAP loss from operations came out to be $915.6 million and non-GAAP income from operations totaled $2.5 million.

    TWLO: What’s Next?

    The fourth quarter closed off with an incredible year of results, as the company produced over $2.8 billion in revenue for the year, with a 61 percent incline year over year. Furthermore, Twilio Segment’s #1 customer data platform, combined with the top cloud communications platform, provides Twilio a unique perspective into the customer journey.

    Global Partnership of TWLO with Teleperformance – Worth it?

    On 25th December 2021, TWLO stated that it has partnered with Teleperformance. This collaboration is fruitful to provide enterprises all over the world with the future generation of cloud contact center solutions. Teleperformance will employ Twilio technologies, including Flex, Twilio’s programmable cloud-based contact center platform. This will help in providing market-leading cloud contact center solutions to its customers.

    Moreover, the company will accomplish it by combining Twilio’s innovative contact center technology with Teleperformance’s unparalleled human talent and empathy, laying the groundwork for the next era of customer interaction experiences. Twilio and Teleperformance want to use this alliance to improve the way customer engagement is handled in businesses of all sizes and structures in the long run. The goal is to collaborate on new solutions that originate from both areas of competence including digitally transformed customer relationship management and the strong development of video as a channel.

  • Biofrontera AG (BFRA) stock has skyrocketed to 13.09% – What’s helping it to move high?

    Biofrontera AG (BFRA) stock has skyrocketed to 13.09% – What’s helping it to move high?

    Biofrontera AG (BFRA) experienced an increase of 13.09% in premarket. The rally seems to follow discussions on social media sites like Reddit. However, the last trading session concluded at $2.98 with an increase of 7.19%.

    Mediation Results by BFRA – What’s up?

    On 19th November 2021, BFRA announced that for the past year, Biofrontera AG has already been in dialogue with Mr. Wilhelm K. T. Zours and Deutsche Balaton AG to resolve legal challenges and other disagreements. Moreover, Mr. Zours is an indirect primary shareholder in Biofrontera AG, owning shares in the company through a variety of businesses. Maruho Deutschland GmbH, a subsidiary of Maruho Co. Ltd. in Japan, is another important shareholder. During the dispute settlement system, the Deutsche Balaton Group and the incumbent Supervisory Board of Biofrontera AG agreed on the Supervisory Board nominees.

    Third Quarter 2021 Results – How was the quarter?

    BFRA reported third-quarter 2021 results on 17th November 2021. The company announced that product revenues came out to be EUR 12,334 thousand. Not only this but cash and cash equivalents were EUR 29,539 thousand. Sales in other European nations climbed by 64% over the reporting year, from EUR 1,349 thousand in 2020 to EUR 2,208 thousand. Biofrontera was able to secure a new license agreement in Europe. European sales include a one-time payment of EUR 50,000 made to the company upon contract completion.

    Moreover, BFRA reflects back on a good nine-month period in 2021, with to considerable business continuity plan in the second and third quarters. Product sales have been returned to pre-pandemic values since the beginning of 2021. Despite the fact that the pandemic had a significant impact on the first few months, the situation has improved significantly.

    Initiation of Clinical Studies – Worth it?

    On 16th November 2021, BFRA reported that clinical studies have been initiated. The studies will improve marketing strategy and increase market share in the main market, the United States, for the FDA-approved prescription drug Ameluz for photodynamic therapy. Last but not the least, patient recruitment will begin before the end of the year.

    About BFRA

    Biofrontera AG is a pharmaceutical firm focused on the research and marketing of dermatological medication and cosmetics. The company, which is based in Germany, creates and sells cutting-edge skin-care, protection, and therapy products. The combination of Ameluz, a topical prescription medication, and the medical equipment BF-RhodoLED for photodynamic therapy of such superficial skin malignancies and precursors is the firm’s main product. Since 2012, Ameluz has been available in the European Union, and since May 2016, it has been available in the United States. In the European Union, the business also sells Belixos, a dermo-cosmetics line that provides specialized skincare for damaged or diseased skin.

  • Imperial Petroleum Inc. (IMPP) stock experienced downfall – Latest News

    Imperial Petroleum Inc. (IMPP) stock experienced downfall – Latest News

    Imperial Petroleum Inc. (IMPP) experienced a decrease of 4.66% in premarket. However, the last trading session closed at $0.66 with a decrease of 8.87%.

    About IMPP

    Imperial Petroleum Inc. is a shipowner that provides seaborne transportation services for petroleum products and crude oil. With a combined capacity of 255,804 deadweight tons, the company owns three M.R. product tankers and one Aframax oil tanker. On the Nasdaq Capital Market, Imperial Petroleum Inc.’s common stock and 8.75 percent Series A Cumulative Redeemable Perpetual Preferred Stock trade under the symbols “IMPP” and “IMPPP,” respectively.

    Closing of $12.0 Million Underwritten Public Offering

    On 3rd February 2022, IMPP announced the closure of a $12.0 Million Underwritten Public Offering. Each unit was made up of one common share and one Class A warrant to purchase one common share, and it was split up as soon as it was issued. Moreover, the Company also conferred the underwriter a 45-day option of purchasing up to an additional 1,440,000 common shares, subsidized warrants, and 1,440,000 Class A warrants. Before underwriting reductions and commissions, as well as expected offering costs, the gross proceeds to the Company were approximately $12.0 million.

    Third Quarter 2021 Financial Results – Latest News by IMPP

    IMPP reported third-quarter 2021 financial results on 21st December 2021. The company announced revenue of $4.1 million. Not only this but voyage expenses and vessels’ operating expenses came out to be $0.7 million and $1.9 million respectively. Moreover, drydocking costs were $0.9 million and EBITDA was around $1.2 million. It’s unclear when COVID-19, the fundamental component that suffocates all economic activity, will start to have a lessening effect on energy demand. From a strategic perspective, the company has the patience to wait while still running the business cautiously, with excellent earnings transparency and a stable capital position as cornerstones.

    What’s Next?

    IMPP is pleased to report that the spin-off of STEALTHGAS’ four tankers into a new publicly-traded company has been completed successfully. The market has been affected by COVID-19 uncertainties, resulting in lower oil demand and crude shipments this year, which has been difficult for ship owners. Based on the carve-out financial statements generated, the company’s third-quarter performance was really impoverished.

  • Sonnet BioTherapeutics Holdings, Inc. (SONN) stock has increased to 5.75% – What’s going on?

    Sonnet BioTherapeutics Holdings, Inc. (SONN) experienced an increase of 5.75% in the aftermarket because the company announced the fiscal year 2022 first-quarter business updates. However, the last trading session closed at $0.30 with a decrease of 4.57%.

    The fiscal Year 2022 First Quarter Business Updates – What’s up?

    SONN announced the fiscal year 2022 first-quarter business and earnings update on 8th February 2022. The company announced that it had $19.4 million cash. Moreover, research and development costs came out to be $4.3 million. Not only this but the general and administrative expenses were $2.1 million. Last but not the least, in 1Q22, the company will generate additional clinical product stability data for the FDA

    Successful Completion of the Discovery Phase by SONN

    On 30th August 2021, SONN reported that after finishing comprehensive studies in a mouse melanoma model, the company has chosen a novel growth candidate. Sonnet’s second bispecific drug combines Interleukin 12 (IL-12) with the company’s Fully Human Albumin Binding (FHAB) platform in this contender. Melanoma and kidney malignancies are the target indications for SON-1410.

    The company is excited to have discovered this newest bispecific candidate, which will enter the next phase of evolution in the fourth quarter of 2021, with the goal of filing an IND in the second half of 2022. This has been possible because of the recently concluded $30 million funding. As SONN keeps building out the immuno-oncology pipeline, the Scientific Advisory Board is very excited by these new findings, as well as the chance to broaden research with IL-18 and IL-12.

    The fiscal Year 2021 Third Quarter Business and Earnings Update by SONN

    SONN reported the Fiscal Year 2021 Third Quarter Business and Earnings Update on 16th August 2021. With the patented Fully Human Albumin Binding pipeline assets and the associated product, the company has kept making many signs of progress towards the clinic all through the quarter. IND submissions for both SON-1010 and SON-080 are on track to be filed with the FDA. SONN feels hopeful that the ability to execute a medicinal payload in a more focused manner than conventional, wild-type cytokines will lead to enhanced potency.